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Abstract Hepatitis B infection remains a major public
health problem globally and in the United States, with
significant use of healthcare resources. Several therapeu-
tic agents active against viral and host targets are
currently available for its treatment. The success of
combination therapy in HIV infection, which has simi-
larities to hepatitis B in both therapeutic targets and
treatment options, stimulated studies on the efficacy and
safety of various combinations of available drugs in the
treatment of hepatitis B infection. In this review, we
analyze the current role of combination therapy in
chronic hepatitis B infection.
Keywords Hepatitis B.Combination therapy.Chronic
hepatitis B
Introduction
Hepatitis B virus (HBV) infection remains a major public
health challenge, with an estimated 730,000 chronically
infected adults in the United States alone and an annual
financial burden of $1.3 billion [1, 2￿]. Currently available
therapeutic options include both parenteral and oral agents,
which act on various host and viral targets. These include
medications such as standard interferon and pegylated
interferon (peg-interferon), which target receptors on the
host cell membranes, and nucleotide and nucleoside
analogues, which inhibit HBV RNA-dependent DNA
polymerase (lamivudine, telbivudine, entecavir, adefovir
dipivoxil, and tenofovir disoproxil fumarate) [3].
The availability of agents acting on different targets
makes the option of combination therapy to achieve better
therapeutic results particularly attractive. The rationale for
the trial of combination therapy in HBV includes the
possibility that an additive effect of various medications
may achieve more effective sustained viral suppression and
a decreased incidence of drug resistance [4￿￿]. The success
of combination therapy for HIV infection provides a model
for this strategy, especially when considering that many
agents available for the treatment of HBV are also part of
combination regimens for HIV.
Several combinations have been tried in the treatment
of HBV in various settings, with varying degrees of
success. Table 1 summarizes the circumstances in which
combination therapy using various regimens has been
tried for HBV. This article reviews the use of combination
therapy for chronic hepatitis B (CHB), and summarizes
the recommendations of major professional societies
regarding the role of combination therapy in current
clinical management of CHB infection. For the purpose
of this review, we defined combination therapy as the
simultaneous use of more than one antiviral strategy with
the aim of achieving clinical improvement in patients with
CHB; sequential treatments with different agents were
excluded.
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Various combinations of interferon with oral agents, and one
or more oral agents, have been tried for treatment-naïve
patients with hepatitis B early antigen (HBeAg)-positive
CHB.Arecentmeta-analysiscombineddatafromrandomized
controlled trials evaluating various treatment strategies in
HBeAg-positive HBV patients [5￿￿]. The three combinations
addressed in this study included peg-interferon with
lamivudine (n=461), lamivudine with telbivudine (n=41),
and lamivudine with adefovir (n=53). Among all treatment
options considered (including monotherapy with various
agents), peg-interferon with lamivudine had the highest rate
of HBeAg loss, although tenofovir monotherapy dominated
all other therapies for other endpoints, including HBV DNA
suppression, normalization of alanine aminotransferase
(ALT), and histological improvement. Combinations of
lamivudine with adefovir or telbivudine did not fare better
than lamivudine monotherapy in final analysis. Data from
this analysis suggest that, based on current data, mono-
therapy with tenofovir or entecavir delivers better outcomes
for HBeAg-positive chronic HBV than the combinations
analyzed.
Hui et al. [6] studied the combination of adefovir and
emtricitabine against adefovir alone in 30 patients for
96 weeks. Although HBV DNA suppression and ALT
normalization were significantly higher in the combination
group, HBeAg seroconversion rate was similar in both
groups. A recent trial of 112 patients evaluated the
combination of tenofovir and emtricitabine against either
tenofovir or entecavir monotherapy, and found that the
combination arm had comparable rates of HBeAg serocon-
version/loss and similar side effect profile compared to
tenofovir monotherapy [7]. Clevudine/emtricitabine combi-
nation for 24 weeks in a mixed population of HBeAg-
positive and HBeAg-negative patients demonstrated no
significant benefits at the end of treatment (24 weeks)
compared to emtricitabine alone, although combination
therapy had more durable posttreatment HBV DNA
suppression at 48 weeks with no difference in HBeAg
seroconversion between groups [8]. The authors did not
provide a breakdown of HBeAg-positive and HBeAg-
negative groups for the 48-week data. A study of
interferon/telbivudine combination was terminated early
because of reports of increased incidence of peripheral
neuropathy in the combination arm [9].
The success of combined interferon and ribavirin therapy
in HBV/hepatitis C virus (HCV)-coinfected patients (dis-
cussed later in this article) led to trials on the use of this
combination in monoinfected HBeAg-positive CHB
patients. Liu et al. [10] studied interferon-α-2b with
ribavirin against interferon alone in 119 patients for
28 weeks. At follow-up after 52 weeks, there was no
Table 1 Indications and combinations tried for various HBV
populations
Indication
a Combinations studied
HBeAg-positive chronic HBV Interferon + lamivudine
Interferon + telbivudine
Interferon + ribavirin
Interferon + thymosin
Lamivudine + adefovir
Lamivudine + telbivudine
Lamivudine + thymosin
Lamivudine + HBV vaccine
Tenofovir + emtricitabine
Adefovir + emtricitabine
Clevudine + emtricitabine
Adefovir + bicyclol
Thymosin + bicyclol
HBeAg-negative chronic HBV Interferon + lamivudine
Interferon + adefovir
Interferon + ribavirin
Clevudine + emtricitabine
Lamivudine + HBV vaccine
HBV and HIV coinfection Interferon + adefovir
Tenofovir + lamivudine
Tenofovir + emtricitabine
Lamivudine + entecavir
HBV and hepatitis C coinfection Interferon + ribavirin
Interferon + lamivudine
Interferon non-responders Interferon + lamivudine
Interferon + GM-CSF
Interferon + HBV vaccine
Lamivudine-resistant HBV Peginterferon + adefovir
Adefovir + lamivudine
Adefovir + entecavir (case reports)
Adefovir + tenofovir (case reports)
Tenofovir + lamivudine (case reports)
Adefovir non-responders Adefovir + lamivudine
Tenofovir + lamivudine
Tenofovir + emtricitabine
Pediatric population Lamivudine + interferon-α
Acute HBV infection Adefovir + lamivudine
Severe HBV reactivation Nucleosides + steroids
Asymptomatic chronic carriers Lamivudine + HBV vaccine
Prevent recurrence after liver
transplantation in
HBV-positive recipients
Lamivudine + HBIG
Adefovir + HBIG
Entecavir + HBIG
Lamivudine + adefovir
Prevent recurrence after liver
transplantation with
HBcAb-positive donor
Lamivudine + HBIG
GM-CSF granulocyte-macrophage colony-stimulating factor, HBcAb
hepatitis B core antibody, HBeAg hepatitis B early antigen, HBIG
hepatitis B immune globulin, HBV hepatitis B virus
aThe current review focuses only on populations with chronic HBV
infection
Curr Hepatitis Rep (2011) 10:98–105 99significant difference in the composite endpoint of HBeAg
seroconversion and undetectable HBV DNA between the
two arms.
Therapeutic vaccination in concert with an antiviral
agent has also been studied for the treatment of CHB.
Senturk et al. [11] studied the effect of adding a pre-S2-
containing vaccine to lamivudine in patients with CHB. Of
19 HBeAg-positive patients treated for 6 months with
lamivudine, 100 mg twice daily, and six doses of pre-S2-
containing vaccine, five (26%) lost HBeAg at the end of
6 months, 18 of 19 had undetectable levels of HBV DNA,
with normalization of ALT in the five who had serocon-
version. At follow-up after 364 weeks, all five who had
seroconverted remained in sustained remission. Because
these authors did not have an untreated comparator arm, or
lamivudine monotherapy, it is difficult to confirm that the
combination was superior to monotherapy alone. In fact,
Vandepapeliere et al. [12] randomly assigned 195 HBeAg-
positive patients to receive lamivudine alone or lamivudine
with hepatitis B surface antigen (HBsAg)/AS02B adjuvant
candidate vaccine for 52 weeks, and found that addition of
this vaccine did not enhance the HBeAg conversion rate.
Hoa et al. [13] randomly assigned 180 patients to a pre-S1/
pre-S2/S vaccine or lamivudine or combination for 6 to
8 months, and found no difference in HBeAg seroconver-
sion among the three groups at 18-months’ follow-up,
although the combination arm had significantly more viral
suppression. Thus, although therapeutic vaccination
remains attractive as part of a combination, studies have
not shown a clear benefit compared to lamivudine mono-
therapy. However, it should be noted that the vaccines used
were slightly different in each of these studies, and thus
direct comparison of results is not possible.
Other compounds that were tried in combination with
more commonly used HBV medications include bicyclol
and thymosin-α. Bicyclol is the active component of a
Chinese herb used for treatment of hepatitis B. Studies have
been reported mainly in the Chinese literature. Combination
of bicyclol with adefovir in one randomized trial achieved
better HBV DNA suppression as compared to adefovir
alone [14]. Thymosin-α, a synthetic hormone initially
isolated from the thymus, has been used in combination
with bicyclol and was reported to have significantly higher
HBeAg conversion rates compared to bicyclol alone [15].
A recent meta-analysis comparing lamivudine/thymosin
combination against lamivudine alone identified signifi-
cantly better outcomes for combination therapy, including
HBeAg seroconversion rates (45% vs 15%) [16]. Thymosin
has also been tried in combination with interferon-α, with
Lim et al. [17] reporting a trend toward increased HBeAg
loss in those who received the combination. These
medications are not widely used in the United States for
management of hepatitis B.
In conclusion, trials to date have not confirmed
superiority for commonly available combinations when
compared to monotherapy for HBeAg-positive chronic
HBV. A recent study from France showed that despite this
lack of superiority, 15% of treatment-naïve HBV patients
were receiving adefovir/lamivudine combination as initial
therapy [18]. The American Association for the Study of
Liver Diseases (AASLD) guidelines recommend mono-
therapy with any of the available agents as first-line therapy
for HBeAg-positive chronic HBV, although peg-interferon,
tenofovir, and entecavir are preferred [19￿￿].
HBeAg-Negative Chronic HBV
Peg-interferon-α is the current standard of therapy for
treatment of HBeAg-negative hepatitis B, although tenofo-
vir and entecavir have been added to the list of preferred
first-line agents in the latest revision of the AASLD
guidelines [19￿￿]. A meta-analysis by Woo et al. [5￿￿]o f
296 HBeAg-negative patients suggested that peg-interferon/
lamivudine was more effective than monotherapy in
achieving undetectable HBV DNA levels, although it was
less effective in normalization of ALT levels. Another
meta-analysis, which included nine trials with 942 patients,
also found no benefit for interferon/lamivudine combina-
tion in HBeAg-negative patients, although the combination
arm had a lower YMDD mutation rate [20]. A recent
randomized trial compared peg-interferon and adefovir
dipivoxil to peg-interferon monotherapy for 48 weeks and
demonstrated higher rates of HBV DNA suppression and
ALT normalization, although sustained viral response at
72 weeks was equivalent in the two arms [21].
Based on reports of possible benefit of peg-interferon/
ribavirin combination among HBV/HCV-coinfected
patients, this combination also was tried for patients with
HBeAg-negative disease. However, a randomized trial in
138 patients with HBeAg-negative disease failed to find
any significant benefit for the combination over peg-
interferon alone [22].
The study by Senturk et al. [11] mentioned above, which
studied a lamivudine/pre-S2 vaccine combination, also
analyzed 29 patients who were HBeAg-negative, and
reported normalization of ALT and loss of HBV DNA in
18 of 29. However, this study did not have a comparator
monotherapy arm.
Thus, various combination therapies for HBeAg-
negative hepatitis B have not established a benefit over
monotherapy, although there has been decreased develop-
ment of resistance with the combination of interferon and
lamivudine. However, availability of more effective medi-
cations (eg, tenofovir and entecavir), which also have low
reported resistance levels, eliminates this advantage.
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HIV and HBV share common routes of entry, and about
10% of all HIV-infected patients are coinfected with HBV
[23]. The success of combination therapy for HIV was a
strong driving force for trials of combination therapy for
HBV. The higher chance of developing resistance to HIV
with oral monotherapy for HBV, when using medications
with some activity against HIV, also prompted the
evaluation of combination therapy for coinfected patients.
A randomized trial from Thailand studied tenofovir/
lamivudine combination against monotherapy with either
agent alone in antiretroviral-naïve HIV/HBV-coinfected
patients, and found that the combination did not do better
than tenofovir alone for HBV [24]. Another study compar-
ing tenofovir/lamivudine combination against tenofovir
monotherapy for lamivudine failures followed 75 patients
over 116 weeks of treatment, and found no significant
benefit for combination over tenofovir monotherapy [25].
However, a cross-sectional analysis of 122 US and
Australian HIV/HBV-coinfected patients on antiretroviral
therapy demonstrated significantly lower HBV DNA levels
in patients using tenofovir in combination with lamivudine
or emtricitabine, than in those using tenofovir or lamivu-
dine alone as part of the HIV regimen [26]. Tenofovir/
emtricitabine-based antiretroviral therapy resulted in unde-
tectable HBV DNA levels in 15 of 16 patients in one trial,
although HBV levels rebounded in those who underwent a
structured treatment interruption [27]. Pessôa et al. [28]
added entecavir to HIV/HBV-coinfected patients who were
already on a lamivudine-based antiretroviral regimen, and
demonstrated significant reductions in HBV DNA levels
with no demonstrable increase in side effects or HIV
viremia.
In a small trial, coinfected patients with lamivudine-
resistant HBV were given peg-interferon/adefovir combi-
nation; no maintenance of on-treatment benefits was
observed after discontinuation of therapy, although the
combination was well-tolerated [29].
Thus, although current data do not indicate a large
benefit for combination therapy, the use of dual-acting
medications in combination is nevertheless the standard of
care in HIV/HBV-coinfected patients because of concerns
about development of HIV resistance. Structured treatment
interruptions for HIV may adversely affect the HBV
infection in such coinfected patients.
HBV/HCV Coinfection
HBV and HCV also share a common route of entry, and an
estimated 18% of patients with chronic HBVare coinfected
with HCV [30]. Active hepatitis in such patients is more
likely from HCV than HBV [30], and hence treatment is
often directed against HCV, with some studies also showing
a concomitant improvement in HBV markers.
A large trial, which included 161 patients with HBV/
HCV coinfection treated with peg-interferon/ribavirin com-
bination, had 11.2% HBsAg clearance rate at the end of
treatment for HCV [31]. However, during the course of
therapy, 77 patients who previously had negative HBV
DNA levels started expressing HBV DNA, although this
was not associated with clinically significant hepatic
disease. A smaller study by Hung et al. [32] reported
similar findings with interferon/ribavirin combination.
Another recent report suggested that any HBV viral
response achieved following such combination therapy
may not be sustained long-term [33].
Marrone et al. [34] studied interferon/lamivudine combi-
nation in eight patients with coinfection and reported HBeAg
seroconversion in three. However, no further studies have
been performed using this combination. No studies are
available for a combination of interferon and ribavirin with
any of the other anti-HBV therapies in coinfected patients.
Thus, current data indicate that treatment of HBV/HCV
coinfection is essentially aimed at the predominant virus,
which in many cases happens to be HCV.
HBV Unresponsive to Interferon
Interferon monotherapy for HBV has only 25% to 40%
therapeutic efficacy, setting the stage for trials in patients
who are unresponsive to such monotherapy [35]. One such
study randomly assigned patients who failed interferon
monotherapy to receive interferon/lamivudine or interferon/
granulocyte-macrophage colony-stimulating factor (GM-
CSF), and noted sustained loss of HBeAg and HBV DNA
suppression in 28% on the interferon/lamivudine arm, as
opposed to 40% in the interferon/GM-CSF arm [35].
However, Schiff et al. [36] studied 238 interferon non-
responders, and found that lamivudine monotherapy out-
performed interferon/lamivudine combination in all
respects, including HBeAg loss. Akyuz et al. [37] studied
45 HBeAg-negative non-responders to interferon, and
found that interferon/lamivudine combination was not
better than lamivudine monotherapy. Heintges et al. [38]
used interferon/hepatitis B vaccination in interferon non-
responders, and reported HBeAg loss in 7 of 18 and
undetectable HBV DNA in 9 of 18 while on therapy,
although posttreatment sustained response rates were not
reported in this trial. Thus, combination therapy does not
appear any more effective than monotherapy for interferon
non-responders. Current AASLD guidelines recommend
monotherapy with tenofovir or entecavir in interferon non-
responders [19￿￿].
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Lamivudine was the first oral therapy available for HBV
infection, and remains an attractive option in many parts of
the world because of its relatively safe side effect profile
and low cost. However, rapid development of resistance is
the major limitation of therapy.
Adefovir added to lamivudine has been studied exten-
sively in patients with lamivudine failure. A recent meta-
analysis included six trials with 442 patients, and concluded
that the combination performed better than adefovir mono-
therapy with respect to HBV DNA suppression and
development of adefovir resistance, although there was no
significant difference in HBeAg seroconversion or ALT
normalization [39]. A 56-month follow-up trial published
after this meta-analysis confirmed the findings of improved
virological suppression with the combination, although
there was no difference in the development of resistance
to adefovir [40].
A trial of 235 patients comparing peginterferon/lamivu-
dine combination against adefovir/lamivudine showed that
addition of peginterferon had a better HBeAg seroconver-
sion rate and greater reduction of quantitative HBsAg assay,
suggesting that this could be a better option for lamivudine-
resistant HBV [41]. Although case reports have suggested
that adefovir/entecavir, adefovir/tenofovir, and tenofovir/
lamivudine combinations may be effective in lamivudine-
resistant patients, no studies are available for these at
present.
Current AASLD guidelines recommend the addition of
adefovir or tenofovir to lamivudine in patients with
lamivudine resistance [19￿￿].
HBV Unresponsive to Adefovir
With increasing use of adefovir, resistance to this agent has
also become a problem. The cumulative resistance at 4 years
is about 15%, and another 30% of patients have primary
non-response [19￿￿]. There are few studies on management
of adefovir non-responsive patients, and the available trials
have looked at combination of medications.
Choe et al. [42] treated six patients who were adefovir
non-responders with tenofovir/lamivudine combination,
resulting in undetectable viral levels in all by 12 months,
with ALT improvement in four of six. A retrospective study
looked at adefovir/lamivudine combination in patients who
had failed sequential lamivudine and adefovir monotherapy,
and had 0% virological breakthrough at 18 months against
55% in patients who were switched to entecavir mono-
therapy [43]. The AASLD guidelines currently recommend
add-on therapy with lamivudine as the first-line option for
managing adefovir non-responders [19￿￿].
Pediatric Population
Children infected with hepatitis B are generally in an
immune-tolerant phase, usually do not achieve HBeAg
seroconversion or sustained HBV DNA reductions, and
hence may not benefit from therapy. There are also
concerns about using nucleoside agents for treatment,
because of the likely need for lifelong therapy and
development of resistance [44￿]. Combination therapy
studies in this population have usually focused on
interferon-based treatments.
Kansu et al. [45] studied 177 children with CHB and
compared simultaneous therapy versus staggered therapy
with interferon and lamivudine; they noted that simulta-
neous therapy produced earlier HBeAg seroconversion
and viral clearance and higher rates of complete response
(55% vs 28%). However, another trial comparing the
combination to interferon alone found that although
HBeAg seroconversion and HBV DNA loss occurred
earlier with combination therapy, the final outcome at
12 months did not differ between the groups [46]. The
current standard of care for children with HBV who are
considered for treatment is interferon or lamivudine
monotherapy [19￿￿].
Side Effects of Combination Therapy
Side effects of combination therapy would be expected to
be more frequent than monotherapy. A recent review from
our group outlines the side effects of the various oral agents
currently available for HBV [47￿]. However, combination
therapy may sometimes give rise to otherwise unanticipated
side effects. A trial on interferon/telbivudine was terminat-
ed early because of high incidence of peripheral neuropathy
[9]. Interferon/ribavirin combination therapy in HBV/HCV-
coinfected patients may lead to new detection of HBV
DNA in patients in whom it was previously suppressed,
although this has not been associated with worsening of
liver function [31, 32]. Hepatic flare has been noted in HIV/
HBV-coinfected patients after initiation of HBV-specific
therapy, and is probably an immune reconstitution syn-
drome, although it is not currently clear if combination
therapy has any worse risk of causing this as compared to
HBV monotherapy [48].
Current Recommendations for Combination Therapy
in Hepatitis B
From our review, it appears that currently there are only
limited circumstances in which combination therapy has an
advantage over monotherapy with one of the newer agents.
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therapy is recommended for the following:
1. Lamivudine or telbivudine resistance: addition of
adefovir or tenofovir to existing treatment, or switch
to tenofovir/emtricitabine combination.
2. Adefovir resistance:
a. Addition of lamivudine, telbivudine, or entecavir to
adefovir
b. Replacing adefovir with tenofovir in combination
with lamivudine or emtricitabine.
c. If previous lamivudine resistance with current
adefovir resistance, replacing adefovir with tenofovir
and lamivudine, emtricitabine, or entecavir.
3. Entecavir resistance: switching to tenofovir/emtricitabine
is one of the options listed.
4. HIV/HBV coinfection where treatment of both pathogens
is indicated:
a. Tenofovir/lamivudine or tenofovir/emtricitabine.
b. Iflamivudine resistance, add tenofovir to lamivudine.
The European Association for the Study of the Liver
(EASL) guidelines are generally similar to AASLD guide-
lines in their recommendations about combination therapy,
with the following differences [49￿]:
1. Tenofovir is considered the preferred add-on therapy
for lamivudine or telbivudine resistance.
2. In adefovir resistance, it is recommended that adefovir
be discontinued and tenofovir added with a second
agent:
a. If N236T substitution, the second agent should be
lamivudine, entecavir, telbivudine, or emtricitabine.
b. If A181T/V substitution, the second agent should
be entecavir or emtricitabine.
3. In entecavir resistance, the recommendation is to add
tenofovir to entecavir.
4. In case of tenofovir resistance, the recommendation is to
add entecavir, lamivudine, telbivudine, or emtricitabine.
This issue was not addressed in the AASLD guidelines.
5. HIV/HBV coinfection:
a. For those needing comanagement of both infections,
tenofovir/emtricitabinecombinationisrecommended.
b. Where HBV is treated first, adefovir/telbivudine
combination is first-line therapy.
The Asian-Pacific Association for the Study of the
Liver (APASL) recommendations for HBV therapy
include the following indications for combination therapy
[50￿]:
1. Lamivudine resistance: add-on adefovir is first-line
therapy.
2. Adefovir resistance: add or switch to lamivudine or
telbivudine or entecavir.
3. Telbivudine resistance: add-on adefovir is recommended.
4. For HIV/HBV coinfection, tenofovir/lamivudine com-
bination is recommended if concurrent treatment of
both infections is required.
Barriers to Combination Therapy
Initial enthusiasm about the potential of combination
therapy for HBV more recently was tempered by equivocal
results of studies. Several barriers currently exist to
combination therapy for HBV. For one, although combina-
tion therapy for HBV has often been modeled after therapy
for HIV, the treatment of HIV involves using at least three
different drugs acting on two different viral targets. The
only viral target for the current crop of HBV medications is
the RNA-dependent DNA-polymerase. Treatment for HIV
is also commonly life-long, despite undetectable viral loads,
based on the understanding that discontinuation of therapy
will lead to recurrence of the infection. The combination
therapy trials for HBV so far have been time-limited, and it
is difficult to predict if longer therapeutic duration might
provide better results without increasing resistance. Long-
term follow-up of patients with HIV/HBV coinfection who
are on medications active against both viruses (eg,
tenofovir/emtricitabine or tenofovir/lamivudine combina-
tions) is more likely to yield an answer to these questions.
Finally, the cost of the medications continues to be an issue
for a large proportion of HBV-infected individuals who live
in third-world countries. The combination of expensive
drugs will be more expensive than monotherapy.
Conclusions
Despite its initial promise, combination therapy for
chronic HBV infection has not been shown to be more
effective than monotherapy in most treatment-naïve
patients. Although combination therapy lowers the
incidence of drug resistance, the availability of oral
monotherapeutic agents withv e r yl o wr e s i s t a n c el e v e l s
eliminates this advantage. Current indications for combi-
nation therapy are limited to special populations, such as
drug-resistant HBV infection and HIV/HBV coinfection.
More trials are currently under way for combination
therapy for various HBV populations.
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